Biochemical markers of bone formation

Clinics in Laboratory Medicine

Volumn 20, Issue 3, 2000, Pages 489-501

  Gundberg, C M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; OSTEOCALCIN; PROCOLLAGEN;

BONE ATROPHY; BONE MASS; FRACTURE; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 0033843507     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0272-2712(18)30049-0     Document Type: Review

References (75)

1. Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: A retrospective and prospective population-based study in women
2. Biochemical markers of bone turnover and prediction of hip bone loss in older women: The Study of Osteoporotic Fractures
3. Thermal instability of the trimeric structure of N-terminal propeptide of human procollagen-type I in relation to assay technology
4. Molecular basis and clinical application of biological markers of bone turnover
5. Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: Relation to calcium kinetics
6. Serum N-terminal osteocalcin is a good indicator for estimating responders to hormone replacement therapy in postmenopausal women
7. Prediction of rapid bone loss in postmenopausal women
8. Screening procedure for women at risk of developing postmenopausal osteoporosis
9. Immunoradiometric assay for intact human osteocalcin(1-49) without cross-reactivity to breakdown products
10. Biochemistry of alkaline phosphatase isoenzymes
11. Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease
12. Biochemical markers of bone turnover reflect femoral bone loss in elderly women
13. Technical and clinical validation of a new immunoradiometric assay for human osteocalcin
14. Bone turnover markers and bone density across the menopausal transition
15. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases
16. Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia
17. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover
18. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease
19. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay
20. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro
21. Markers of bone resorption predict hip fractures in elderly women. The EPIDOS study
22. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis
23. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The OFELY study
24. Monoclonal antibody assay for measuring bonespecific alkaline phosphatase activity in serum
25. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial
26. Biology, physiology, and clinical chemistry of osteocalcin
27. Vitamin K dependent proteins of bone and cartilage
28. Multiple immunoreactive forms of osteocalcin in uremic serum
29. Response of biochemical markers of bone turnover to hormone replacement therapy: Impact of biological variability
30. Osteocalcin and matrix Gla protein: Vitamin K-dependent proteins in bone
31. Prevention of bone loss with alendronate in postmenopausal women under the 60 years of age
32. Postmenopausal estrogens protect against fractures of hip and distal radius
33. External thoracic duct-venous shunt in conscious pigs for long-term studies of connective tissue metabolites in lymph
34. Intraindividual variability in bone markers in the urine
35. Bone morphogenic protein-1: The type of procollagen C-proteinase
36. Biosynthesis of the collagens
37. Bone mineral density and biochemical markers of bone turnover in healthy elderly men and women
38. Bone alkaline phosphatase: Methods of quantitation and clinical utility
39. Use of bone alkaline phosphatase to monitor alendronate therapy in individual postmenopausal osteoporotic women
40. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
41. Structural and functional roles of glycosyl-phosphatidylinositol in membranes
42. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
43. Analytical and clinical evaluation of a method to quantify bone alkaline phosphatase, a marker of osteoblastic activity
44. Immunoassay for intact amino-terminal propeptide of human type I procollagen
45. Relationship of bone markers to bone density and fractures
46. Serum carboxy-terminal propetide of human type I procollagen in patients with primary hyperparathyroidism: Studies in basal conditions and after parathyroid surgery
47. Serum osteocalcin and bone mineral density at various skeletal sites: A study performed with three different assays
48. Estimation of bone mineral density and bone loss by means of bone metabolic markers in postmenopausal women
49. Sandwich enzyme immunoassay of osteocalcin in serum with use of an antibody against human osteocalcin
50. The reproducibility of bone-related biochemical variables in post-menopausal women
51. Diurnal rhythm in serum activity of wheat-germ lectin precipitable alkaline phosphatase: Temporal relationships with the diurnal rhythm of serum osteocalcin
52. Purification and characterization of a peptide from the carboxy-terminal region of chick tendon procollagen type I
53. Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development reference interval and hypovitaminosis D induced hyperparathyroidism
54. Two-site enzyme immunoassay for measuring intact human osteocalcin in serum
55. Clinical observations with a new specific assay for bone alkaline phosphatase: A cross-sectional study in osteoporotic and pagetic subjects and a longitudinal evaluation of the response to ovariectomy, estrogens, and bisphosphonates
56. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: Prediction of bone mass changes during treatment
57. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women
58. High bone turnover is associated with low bone mass and spinal fracture in postmenopausal women
59. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation
60. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates
61. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies
62. Rapid bone loss is associated with increased levels of biochemical markers
63. Basic science and clinical utility of biochemical markers of bone turnover
64. Type I procollagen propeptide ratio responds rapidly to pamidronate in Paget's disease of bone
65. Circulating C-terminal propetide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells
66. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women
67. Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women
68. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: A three year follow-up study
69. Comparison of bone and total alkaline phosphatase activity on bone turnover during menopause and in patients with established osteoporosis
70. Multiple osteocalcin fragments in human urine and serum as detected by a midmolecule osteocalcin radioimmunoassay
71. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium crosslinks
72. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women. The EPIDOS study
73. Structure of the human liver/bone/kidney alkaline phosphatase gene
74. Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization
75. Comparison of total and bone-specific alkaline phosphastase in patients with nonskeletal disorders or metabolic bone disease